Following a natriuresis guided protocol in diuretic use led to a 64% increased natriuresis after 24 hours. In addition, duration of hospitalisation was 1 day shorter in the intervention group in the prospective ENACT-HF trial.
Current guidelines recommend a standardised diuretic protocol for diuretic use that has not been evaluated prospectively. To test whether a standardised diuretic protocol is superior to standard-of-care, Dr Jeroen Dauw (AZ Sint-Lucas in Ghent, Belgium) performed the prospective, multicentre, open-label, non-randomised, pragmatic ENACT-HF trial [1]. The study included 29 centres in 18 countries worldwide. In each centre, standard-of-care was compared with a standardised diuretic protocol in 2 sequential phases of recruitment: standard-of-care was used in phase 1, and the standardised protocol was followed in phase 2.
All 401 study participants had been admitted with acute heart failure and had at least 1 sign of volume overload. The primary endpoint was natriuresis after 1 day. Secondary endpoints included natriuresis and diuresis after 2 days, weight loss after 2 days, change in a congestion score, and duration of hospitalisation.
Following the standardised protocol led to an increase in natriuresis of 64% after 1 day (natriuresis after 1 day was 174 mmol in the standard-of-care group compared with 282 mmol in the protocol group; 95% CI 1.37–1.95; P<0.001). A predefined subgroup analysis revealed that patients had a benefit independent of age, sex, kidney function, and left ventricular ejection fraction. “Those with a lower glomerular filtration rate had even a higher benefit,” Dr Dauw said.
The superiority of the protocol was also seen in both natriuresis and diuresis on day 2. They were significantly higher in the group following the diuretic protocol (P<0.001 for both comparisons). No difference was seen in weight loss and congestion score after 2 days, but weight loss is possibly less reliable in a pragmatic design. “We had a high congestion score already at the beginning of the trial, it might therefore take more time for these patients to see a difference,” Dr Dauw said. Patients following the protocol had a 1-day shorter duration of hospitalisation. There was no difference in the safety endpoints between standard-of-care and the diuretic protocol.
-
- Dauw J. Efficacy of a standardised diuretic protocol in acute heart failure. Session Late breaking clinical trials: acute heart failure and patients monitoring, Heart Failure 2023, 20–23 May, Prague, Czechia.
Copyright ©2023 Medicom Medical Publishers
Posted on
« Excellent results for C21 in idiopathic pulmonary fibrosis Next Article
Aficamten may lower symptom burden in non-obstructive hypertrophic cardiomyopathy »
Table of Contents: HFA 2023
Featured articles
Significant NT-proBNP reduction with sacubitril/valsartan in HF patients with ejection fraction >40%
Online First
DAPA MODA trial: Dapagliflozin improves multiple parameters of cardiac remodelling
A single nutritional intervention can reduce adverse outcomes in acute heart failure
Obese HF patients with type 2 diabetes at high risk to develop depression
Aficamten may lower symptom burden in non-obstructive hypertrophic cardiomyopathy
ENACT-HF: Standardised diuretic protocol improves natriuresis in acute heart failure
Significant NT-proBNP reduction with sacubitril/valsartan in HF patients with ejection fraction >40%
Protein-bound uremic toxins predict HF events and death in patients with chronic kidney disease
Stronger legs mean a lower risk of developing HF after AMI
AI-based technology successful in SARS-CoV-2 symptoms screening
NUDGE-FLU: Repeated electronic nudges improve flu vaccination rates in patients with HF
Haemodynamic monitoring improves quality of life and lowers hospitalisations in HF patients
Copper chelating agent improves biomarkers and quality of life in HF patients
Patisiran benefits maintained over 18 months in patients with transthyretin amyloidosis
Vascular Endothelial Growth Factor C: a novel potential biomarker for peripheral tissue congestion in acute heart failure
Obstructive sleep apnea: highly prevalent in patients with acute ischaemic stroke
Related Articles
Cryptogenic-stroke features and cancer status may be linked
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy